Fig. 4: Genetic and epigenetic alteration landscape of HGOC with confirmed best response of CR/PR (left) or PD (right). | Nature Communications

Fig. 4: Genetic and epigenetic alteration landscape of HGOC with confirmed best response of CR/PR (left) or PD (right).

From: Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Fig. 4

Methylation levels shown are at screening. *Short variant include nonsense, missense, frameshift, and splice site alterations. All reported alterations are deleterious or likely deleterious. BRCA BRCA1 or BRCA2, CR complete response, HGOC high-grade ovarian carcinoma, HRR homologous recombination repair, LOH loss of heterozygosity, mut mutated, PD progressive disease, PR partial response, RTK receptor tyrosine kinase, wt wild type.

Back to article page